Amgen Closes $4.0 Billion Senior Unsecured Notes Offering

summarizeSummary

Amgen Inc. announced the successful closing of its $4.0 billion senior unsecured notes offering, securing substantial capital to enhance financial flexibility.

check_boxKey Events · Financing and Capital Events · AMGN

• $4.0 Billion Senior Notes Offering Closed

  Amgen Inc. completed the issuance and sale of $4.0 billion in aggregate principal amount of senior unsecured notes across four tranches.

• Significant Net Proceeds Secured

  The offering generated approximately $3.96 billion in net proceeds for the company after deducting underwriters' discounts and estimated offering expenses.

• Debt Structure and Terms

  The notes feature maturities ranging from 2031 to 2056 with interest rates between 4.200% and 5.650%, and rank equally with other senior unsecured debt.

• Formalizes Prior Disclosures

  This filing formalizes the closing of the offering, following the S-3ASR registration on February 13, 2026, and the finalization of terms announced on February 17, 2026.

auto_awesomeAnalysis · AMGN · Life Sciences

This 8-K formally reports the successful closing of Amgen Inc.'s previously announced $4.0 billion senior unsecured notes offering. The transaction, which was initiated with an S-3ASR registration on February 13, 2026, and had its terms finalized on February 17, 2026, provides the company with approximately $3.96 billion in net proceeds. This substantial capital infusion significantly enhances Amgen's financial flexibility, enabling it to fund general corporate purposes, pursue strategic initiatives, or refinance existing debt without direct equity dilution. The successful execution of this large debt offering underscores Amgen's strong credit profile and continued access to capital markets on favorable terms.